BCR-ABL1-positive CML and BCR-ABL1-negative chronic myeloproliferative disorders: Some common and contrasting features

Leukemia

Volumn 22, Issue 11, 2008, Pages 1975-1989

  Cross, N C P ^a   Daley, G Q ^b   Green, A R ^c   Hughes, T P ^d   Jamieson, C ^e   Manley, P ^f   Mughal, T ^g   Perrotti, D ^h   Radich, J ⁱ   Skoda, R ^j   Soverini, S ^k   Vainchenker, W ^l   Verstovsek, S ^m   Villeval, J L ^l   Goldman, J M ⁿ  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^d INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f NOVARTIS PHARMA AG   (Switzerland)

^g KING'S COLLEGE LONDON   (United Kingdom)

^h THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

ⁱ Fred Hutchinson Cancer Research Center   (United States)

^j UNIVERSITY HOSPITAL BASEL   (Switzerland)

^k UNIVERSITY OF BOLOGNA   (Italy)

^l INSERM   (France)

^m UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

ⁿ HAMMERSMITH HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 DIMETHYLAMINO 1 PYRROLIDINYLMETHYL) 3 TRIFLUOROMETHYL N [4 METHYL 3 [[4 (5 PYRIMIDINYL) 2 PYRIMIDINYL]AMINO]PHENYL]BENZAMIDE; AP 24534; AURORA KINASE INHIBITOR; AZD 1480; BCR ABL PROTEIN; BCR ABL1 PROTEIN; BOSUTINIB; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; DASATINIB; DCC 2036; ENZYME INHIBITOR; ERLOTINIB; IMATINIB; INCB 018424; JANUS KINASE 2; KW 2449; LESTAURTINIB; MICRORNA; NILOTINIB; PHA 739358; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; SB 1518; SGX 393; SGX 70393; TG 101209; TG 101348; UNCLASSIFIED DRUG; XL 019; XL 228;

BLAST CELL CRISIS; BONE MARROW SUPPRESSION; BRAIN TOXICITY; CD34 SELECTION; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COMPARATIVE GENOMIC HYBRIDIZATION; DIARRHEA; DISEASE COURSE; DOUBLE STRANDED DNA BREAK; DOWN REGULATION; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MEGADOSE; EDITORIAL; ENZYME ACTIVITY; ENZYME INHIBITION; ERYTHROCYTOSIS; EXON; GENE DELETION; GENE MUTATION; GENOMIC INSTABILITY; HETEROZYGOSITY; HOMOLOGOUS RECOMBINATION; HUMAN; LEUKEMIA CELL; MALIGNANT TRANSFORMATION; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; NAUSEA; NEUROTOXICITY; NONHUMAN; PATHOGENESIS; PHENOTYPE; PHILADELPHIA 1 CHROMOSOME; POINT MUTATION; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TRANSCRIPTION REGULATION; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 56349129388     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.231     Document Type: Editorial

References (168)

1. Dameshek W. Some speculations on the myeloproliferative syndromes. (Editorial). Blood 1951; 6: 372-375.
2. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2007; 22: 14-22.
3. Fialkow PJ, Gartler SM, Yoshida A. Clonal origin of chronic myelocytic leukemia in man. Proc Natl Acad Sci USA 1967; 58: 1468-1471.
4. Fialkow PJ, Martin PJ, Najfeld V, Penfold GK, Jacobson RJ, Hansen JA. Evidence for a multistep pathogenesis of chronic myelogenous leukemia. Blood 1981; 58: 158-163.
5. Raskind WH, Farraris AM, Najfeld V, Jacobson RJ, Moohr JW, Fialkow PJ et al. Further evidence for the existence of a clonal Ph-negative stage in some cases of Ph-positive chronic myelocytic leukemia. Leukemia 1993; 7: 1163-1167.
6. Takahashi N, Miura I, Saitoh K, Miura AB. Lineage involvement of stem cells bearing the Philadelphia chromosome in chronic myeloid leukemia in the chronic phase as shown by a combination of fluorescence activated cell sorting fluorescence in situ hybridization. Blood 1998; 92: 4758-4763.
7. Spencer A, Yan XH, Chase A, Goldman JM, Melo JV. BCR-ABL positive lymphoblastoid cells display limited proliferative capacity under in vitro culture conditions. Br J Haematol 1996; 94: 654-658.
8. Daley GQ, van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210 BCR/ABL gene of the Philadelphia chromosome. Science 1990; 247: 824-830.
9. Kelliher MA, McLaughlin J, Witte ON, Rosenberg N. Induction of a chronic myelogenous leukemia-like syndrome with v-abl and BCR/ABL. Proc Nat Acad Sci USA 1990; 87: 6649-6653.
10. Elefanty AG, Hariharan IK, Cory S. bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice. EMBO J 1990; 9: 1069-1078.
11. Li S, Ilaria Jr RL, Million RP, Daley GQ, Van Etten RA. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med 1999; 189: 1399-1412.
12. Huettner CS, Zhang P, van Etten RA, Tenen DG. Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat Genet 2000; 24: 57-60.
13. Huettner CS, Koschmieder S, Iwasaki H, Iwasaki-Arai J, Radomska HS, Akashi K et al. Inducible expression of BCR/ABL using human CD34 regulatory elements results in a megakaryocytic myeloproliferative syndrome. Blood 2003; 102: 3363-3370.
14. Zaccaria A, Valenti AM, Donti E, Gozzetti A, Ronconi S, Spedicato F. Persistence of chromosomal abnormalities additional to the Philadelphia chromosome after Philadelphia chromosome disappearance during imatinib therapy for chronic myeloid leukemia. Haematologica 2007; 92 564-565.
15. Bumm T, Muller C, Al-Ali H-K, Krohn K, Shepherd P, Schmidt E. Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood 2003; 101: 1941-1949.
16. Miglino M, Grasso R, Varaldo R, Fugazza A, Colombo N, Clavio M. Molecular analysis of imatinib-induced complete cytogenetic responses in chronic myelogenous leukemia. Leuk Lymph 2006; 47: 1348-1351.
17. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C et al A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144-1148.
18. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-1061.
19. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ et al Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387-389.
20. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR et al. A gain-of-ffunction mutation of JAK2 in myeloproliferative disorders. New Engl J Med 2005; 352: 1779-1790.
21. V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 2006; 108: 1652-1660.
22. Wernig G, Mercher T, Okabe R, Levine RL, Lee BH, Gilliland DG. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 2006; 107: 4274-4281.
23. Bumm TG, Elsea C, Corbin AS, Loriaux M, Sherbenou D, Wood L et al. Characterization of murine JAK2V617F-positive myeloproliferative disease. Cancer Res 2006; 66: 11156-11165.
24. Zaleskas VM, Krause DS, Lazarides K, Patel N, Hu Y, Li S et al. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. PLoS ONE 2006; 1: E18.
25. Tiedt R, Hao-Shen H, Sobas MA, Looser R, Dirnhofer S, Schwaller J et al. Ratio of mutant JAK2-V617F to wild type JAK2 determines the MPD phenotypes in transgenic mice. Blood 2007; 111: 3931-3940.
26. Shide K, Shimoda HK, Kumano T, Karube K, Kameda T, Takenaka K et al Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F. Leukemia 2008; 22: 87-95.
27. V17F causes myeloproliferative disorders in mice. Blood 2008; 111: 5109-5117.
28. Cario H, Goerttler PS, Steimle C, Levine RL, Pahl HL. The JAK2V617F mutation is acquired secondary to the predisposing alteration in familial polycythaemia vera. Br J Haematol 2005; 130: 800-801.
29. Bellanne-Chantelot C, Chaumarel I, Labopin M, Bellanger F, Barbu V, De Toma C et al. Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood 2006; 108: 346-352.
30. Kralovics R, Stockton DW, Prchal JT. Clonal hematopoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the disease. Blood 2003; 102: 3793-3797.
31. Pietra D, Li S, Brisci A, Passamonti F, Rumi E, Theocharides A et al Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood 2008; 111 1686-1689.
32. Landgren O, Goldin LR, Kristinsson SY, Helgadottir EA, Samuelsson J, Björkholm M. Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24577 first-degree relatives of 11039 patients with myeloproliferative neoplasms in Sweden. Blood 2008, 112: 2199-2204.
33. Kralovics R, Teo SS, Li S, Theocharides A, Buser AS, Tichelli A et al Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood 2006; 108: 1377-1380.
34. Nussenzveig RH, Swierczek SI, Jelinek J, Gaikwad A, Liu E, Verstovsek S et al. Polycythemia vera is not initiated by JAK2V617F mutation. Exp Hematol 2007; 35: 32-38.
35. Pardanani A, Lasho TL, Finke C, Mesa RA, Hogan WJ, Ketterling RP et al. Extending Jak2V617F and MpIW515 mutation analysis to single hematopoietic colonies and B and T lymphocytes. Stem Cells 2007; 25: 2358-2362.
36. Kramer A, Reiter A, Kruth J, Erben P, Hochhaus A, Muller M et al. JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia. Lancet Oncol 2007; 8: 658-660.
37. Li S, Kralovics R, De Libero G, Theocharides A, Gisslinger H, Skoda RC. Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations. Blood 2008; 111: 3863-3866.
38. Campbell PJ, Baxter EJ, Beer PA, Scott LM, Bench AJ, Huntly BJ et al Mutation of JAK2 in the myeloproliferative disorders: Timing, clonality studies, cytogenetic associations, and role in leukemic transformation. Blood 2006; 108: 3548-3555.
39. Theocharides A, Boissinot M, Girodon F, Garand R, Teo SS, Lippert E et al. Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood 2007; 110: 375-379.
40. Pasqualucci L, Li S, Meloni G, Schnittger S, Gattenlohner S, Liso A et al. NPM1-mutated acute myeloid leukaemia occurring in JAK2-V617F+ primary myelofibrosis: De-novo origin? Leukemia 2008; 22: 1459-1463.
41. Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005; 353: 33-45.
42. Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT et al Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: A prospective study. Lancet 2005; 366: 1945-1953.
43. Tefferi A, Lasho TL, Schwager SM, Steensma DP, Mesa RA, Li CY et al The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: Lineage specificity and clinical correlates. Br J Haematol 2005; 131: 320i-328i.
44. Barosi G, Bergamaschi G, Marchetti M, Vannucchi AM, Guglielmelli P, Antonioli E et al. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood 2007; 110: 4030-4036.
45. Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis, N Engl J Med 2007; 356: 459-468
46. Percy MJ, Scott LM, Erber WN, Harrison CN, Reilly JT, Jones FG et al The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels. Haematologica 2007; 92: 1607-1614.
47. Scott LM, Scott MA, Campbell PJ, Green AR. Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood 2006; 108: 2435-2417.
48. Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006; 3: E270.
49. Guglielmelli P, Pancrazzi A, Bergamaschi G, Rosti V, Villani L, Antonioli E et al. Anaemia characterises; patients with myelofibrosis harbouring Mpl mutation. Br J Haematol 2007; 137 244-247.
50. Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M et al MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006; 108: 3472-3476.
51. Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med 2006; 355: 2452-2466.
52. Penserga PJ, Skorski T. Fusion tyrosine kinases: A result and cause of genomic instability. Oncogene 2007; 26: 11-20.
53. Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 2007; 7: 441-453.
54. Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 2005; 5: 172-183.
55. Calabretta B, Perrotti D. The biology of CML blast crisis. Blood 2004; 103: 4010-4022.
56. Jiang X, Saw KM, Eaves A, Eaves C. Instability of BCR-ABL gene in primary and cultured myeloid leukemia stem cells. J Nat Cancer Inst 2007; 99: 680-693.
57. Rassool FV, Gaymes TJ, Omidvar N, Brady N, Beurlet S, Pla M et al. Reactive oxygen species, DNA damage, and error-prone repair: A model for genomic instability with progression in myeloid leukemia? Cancer Res 2007; 67: 8762-8771.
58. Nowicki MO, Falinski R, Koptyra M, Slupianek A, Stoklosa T, Gloc E et al. BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks. Blood 2004; 104: 3746-3753.
59. Nieborowska-Skorska M, Stoklosa T, Datta M, Czechowska A, Rink L, Slupianek A et al. ATR-Chk1 axis protects BCR/ABL leukemia cells from the lethal effect of DNA double-strand breaks. Cell Cycle 2006; 5: 994-1000.
60. Stoklosa T, Poplawski T, Koptyra M, Nieborowska-Skorska M, Basak G, Slupianek A et al. BCR-/ABL inhibits mismatch repair to protect from apoptosis and induce point mutations. Cancer Res 2008; 68: 2576-2580.
61. Slupphaug G, Kavli B, Krokan HE. The interacting pathways for prevention and repair of oxidative DNA damage. Mutat Res 2003; 531: 231-251.
62. Canitrot Y, Falinski R, Louat T, Laurent G, Cazaux C, Hoffmann JS et al. p210 BCR/ABL kinase regulates nucleotide excision repair (NER) and resistance to UV radiation. Blood 2003; 102: 2632-2637.
63. Karran P. DNA double strand break repair in mammalian cells. Curr Opin Genet Dev 2000; 10: 144-150.
64. Brady N, Gaymes TJ, Cheung M, Mufti GJ, Rassool FV. Increased error-prone NHEJ activity in myeloid leukemias is associated with DNA damage at sites that recruit key nonhomologous end-joining proteins. Cancer Res 2003; 63: 1798-1805.
65. Slupianek A, Schmutte C, Tombline G, Nieborowska-Skorska M, Hoser G, Nowicki MO et al. BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance. Mol Cell 2001; 8: 795-806.
66. Slupianek.A, Nowicki MQ, Koptyra M, Skorski T. BCR/ABL modifies the kinetics and fidelity of DNA double-strand breaks repair in. hematopoietic cells. DNA Repair (Amst) 2006; 5 243-250.
67. Gaymes TJ, Mufti GJ, Rassool FV. Myeloid leukemias have increased activity of the nonhomologous end-joining pathway and concomitant DNA misrepair that is dependent on the Ku70/86 heterodimer. Cancer Res 2002; 62: 2791-2797.
68. Koptyra M, Cramer K, Slupianek A, Richardson C, Skorski T. BCR/ABL promotes accumulation of chromosomal aberrations induced by oxidative and genotoxic stress. Leukemia 2008, e-pub ahead of print.
69. Giehl M, Fabarius; A, Frank O, Erben P,.Zheng C, Hafner M et al. Expression of the p210BCR-ABL oncoprotein drives centrosomal hypertrophy and clonal evolution in human, U937 cells. Leukemia 2007; 21 1971-1976.
70. Fanta S, Sonnenberg M, Skorta I, Duyster J, Miething, C, Aulitzky WE et al. Pharmacological inhibition of c-Abl compromises genetic stability and DNA repair in Bcr-Abl-negative cells. Oncogene-2008; 27: 4380-4384.
71. Slupianek A, Hoser G, Majsterek I, Bronisz̄ A, Malecki M, Blasiak J et al. Fusión tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis. Mol Cell Biol 2002; 22: 4189-4201.
72. Macdonald D, Cross NC. Chronic myeloproliferative disorders: The role of tyrosine kinases in pathogenesis, diagnosis and therapy. Pathobiology 2007; 74: 81-88.
73. Li X, Levine R, Tong W, Wernig G, Pikman Y, Zarnegar S et al. Expression of a homodimeric type I cytoldne receptor is required for JAK2V6171F-mediated transformation. Proc Nat Acad Sci USA 2005; 102: 18962-18967.
74. Delhommeau F, Pisani DF, James C, Casadevall N, Constantinescu S, Vainchenker W. Oncogenic mechanisms in myelo-proliferative disorders. Cell Mol Life Sci 2006; 63: 2939-2953.
75. Gangat N, Strand J, Lasho TL, Finke CM, Knudson RA, Pardanani A et al Cytogenetic studies at diagnosis in polycythemia Vera: Clinical and JAK2V617F allele burden correlates. Eur J Haematol 2008; 80: 197-200.
76. Tefferi A, Mesa RA, Schroeder G, Hanson CA, Li CY, Dewald GW. Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia. Br J Haematol 2001; 113: 763-771.
77. Garcon L, Rivat C, James C, Lacout C, Camara-Clayette V, Ugo V et al Constitutive activation of STAT5 and Bcl-xL overexpression can induce endogenous erythroid colony formation in human primary cells. Blood 2006; 108: 1551-1554.
78. Walz C, Crowley BJ, Hudon HE, Gramlich JL, Neuberg DS, Podar K et al Activated Jak2 with the V617F point mutation promotes G1/S phase transition. J Biol Chem 2006; 281: 18177-18183.
79. Plo I, Nakatake M, Malivert L, de Villartay J-P, Giraudier S, Villeval JL et al. JAK2 stimulates homologous recombination and genetic instability: Potential implication in the heterogeneity of myeloproliferative disorders. Blood 2008; 112: 1402-1412.
80. Dupont S, Masse A, James C, Teyssandier I, Lecluse Y, Larbret F et al The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. Blood 2007; 110: 1013-1021.
81. Jaffe ES, Harris NL, Stein H, Vardiman JWE, Lyon (eds). World Health Organization Classification of Tumour. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, 2001.
82. Krämer A. JAK2-V617F and BCR-ABL-Double jeopardy? Leuk Res 2008; 32: 1489-1490.
83. Bocchia M, Vannucchi AM, Gozzetti A, Guglielmelli P, Poli G, Crupi R et al. Insights into JAK2-V617F mutation in CML. Lancet Oncol 2007; 8: 864-866.
84. Nakabeppu Y, Sakumi K, Sakamoto K, Tsuchimoto D, Tsuzuki T, Nakatsu Y. Mutagenesis and carcinogenesis caused by the oxidation of nucleic acids. Biol Chem 2006; 387: 373-379.
85. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876-880.
86. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J et al Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002; 2: 117-125.
87. Cowan-Jacob SW, Fendrich AG, Floersheimer A, Furet P, Liebetanz J, Rummel G et al. Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukemja. Acta Crystallographica 2007; D63: 80-93.
88. Hochhaus A, Kreil S, Corbin AS, La Rosee P, Muller MC, Lahaye T et al Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002; 16: 2190-2196.
89. Branford S, Rudzki Z, Walsh S, Grigg A, Arthur C, Taylor K et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 2002; 99: 3472-3475.
90. von Bubnoff N, Schneller F, Peschel C, Duyster J. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: A prospective study. Lancet 2002; 359: 487-491.
91. Soverini S, Colarossi S, Gnani A, Rosti G, Castagnetti F, Poerio A et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: A study by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res 2006; 12: 7374-7379.
92. Apperley JF. Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007; 8: 1018-1029.
93. Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, Lai JL, Philippe N, Facon T et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 2002; 100: 1014-1018.
94. Willis SG, Lange T, Demehri S, Otto S, Crossman L, Niederwieser D et al. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: Correlation with clonal cytogenetic evolution but not response to therapy. Blood 2005; 106: 2128-2137.
95. Holtz MS, Slovak ML, Zhang F, Sawyers CL, Forman SJ, Bhatia R. Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood 2002; 99: 3792-3800.
96. Graham SM, Jorgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002; 99: 319-325.
97. Copland M, Hamilton A, Elrick LJ, Baird JW, Allan EK, Jordanides N et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006; 107: 4532-4539.
98. Cortes J, O'Brien S, Kantarjian H. Discontinuation of imatinib therapy after achieving a molecular response. Blood 2004; 104: 2204-2205.
99. Bhatia R, Holtz M, Niu N, Gray R, Snyder DS, Sawyers CL et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003; 101: 4701-4707.
100. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408-2417.
101. Sorel N, Bonnet ML, Guillier M, Guilhot F, Brizard A, Turhan AG. Evidence of ABL-kinase domain mutations in highly purified primitive stem cell populations of patients with chronic myelogenous leukemia. Biochem Biophys Res Commun 2004; 323: 728-730.
102. Thomas RK, Nickerson E, Simons JF, Janne PA, Tengs T, Yuza Y et al Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat Med 2006; 12: 852-855.
103. Thomas RK, Baker A, DeBiasi RM, Winckler W, LaFramboise T, Lin MW et al. High-throughput oncogene mutation profiling of human cancer. Nat Genet 2007; 39: 347-351.
104. Hughes T, Branford S. Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia. Blood Rev 2006; 20: 29-41.
105. Melo JV, Chuah C. Resistance to imatinib mesylate in chronic myeloid leukaemia. Cancer Lett 2007; 249: 121-132.
106. Branford S. Chronic myeloid leukemia: Molecular monitoring in clinical practice. Hematology. American Society of Hematology Educational Program 2007, 376-383.
107. Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A, Szer J et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003; 102: 276-283.
108. Soverini S, Martinelli G, Rosti G, Bassi S, Amabile M, Poerio A et al ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: A study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol 2005; 23: 4100-4109.
109. Nicolini FE, Corm S, Le QH, Roche-Lestienne C, Preudhomme C. Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: A retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP). Leukemia 2006; 20: 1061-1066.
110. Shah N, Skaggs B, Branford S, Hughes TP, Nicoll JM, Paquette RL. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest 2007; 117: 2562-2569.
111. Griswold IJ, MacPartlin M, Bumm T, Goss VL, O'Hare T, Lee KA et al Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib. Mol Cell Biol 2006; 26: 6082-6093.
112. Skaggs BJ, Gorre ME, Ryvkin A, BurgessMR, Xie Y, Komisopoulou E et al Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants. Proc Natl Acad Sci USA 2006; 103: 19466-19471.
113. Branford S, Rudzki Z, Miller B, Hughes TP. Mutations in the catalytic core (P-loop) of the BCR-ABL kinase domain of imatinib-treated chronic myeloid leukemia patients in chronic phase are strongly associated with imminent progression to blast crisis. Blood 2003; 102: 71a (abstract).
114. Branford S, Rudzki Z, Parkinson I, Grigg A, Taylor K, Seymour JF et al. Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood 2004; 104: 2926-2932.
115. Soverini S, Colarossi S, Gnani A, Castagnetti F, Rosti G, Bosi C et al. Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. Haematologica 2007; 92 401-404.
116. O'Hare T, Eide CA, Deininger MW. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 2007; 110: 2242-2249.
117. O'Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005; 65: 4500-4505.
118. Weisberg E, Manley P, Mestan J, Cowan-Jacob S, Ray A, Griffin JD et al. AMN107 (nilotinib): A novel and selective inhibitor of BCR-ABL. Br J Cancer 2006; 94: 1765-1769.
119. Bradeen HA, Eide CA, O'Hare T, Johnson KJ, Willis SG, Lee FY et al Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: High efficacy of drug combinations. Blood 2006; 108: 2332-2338.
120. Burgess MR, Skaggs BJ, Shah NP, Lee FY, Sawyers CL. Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc Natl Acad Sci USA 2005; 102: 3395-3400.
121. von Bubnoff N, Manley PW, Mestan J, Sanger J, Peschel C, Duyster J. Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107). Blood 2006; 108: 1328-1333.
122. Ray A, Cowan-Jacob SW, Manley PW, Mestan J, Griffin JD. Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study. Blood 2007; 109: 5011-5015.
123. Reiter A, Walz C, Cross NCP. Tyrosine kinases as therapeutic targets in BCR-ABL negative chronic myeloproliferative disorders. Curr Drug Targets 2007; 8: 205-216.
124. Ahuja H, Bar-Eli M, Advani SH, Benchimol S, Cline MJ. Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia. Proc Natl Acad Sci USA 1989; 86: 6783-6787.
125. Radich JP, Dai H, Mao M, Oehler V, Schecter J, Druker B et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci USA 2006; 103: 2794-2799.
126. Schultheis B, Carapeti-Marootian M, Hochhaus A, Weisser A, Goldman JM, Melo JV. Overexpression of SOCS-2 in advanced stages of chronic myeloid leukemia: Possible inadequacy of a negative feedback mechanism. Blood 2002; 99: 1766-1775.
127. Yong A, Szydlo RM, Goldman JM, Apperley JF, Melo JV. Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML. Blood 2006; 107: 205-212.
128. Guo Z, Dose M, Kovalovsky D, Chang R, O'Neil J, Look AT et al. β-Catenin stabilization stalls the transition from double-positive to single-positive stage and predisposes thymocytes to malignant transformation. Blood 2007; 109: 5463-5472.
129. Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004; 351: 657-667.
130. Passegue E, Wagner EF, Weissman IL. JunB deficiency leads to a myeloproliferative disorder arising from hematopoietic stem cells. Cell 2004; 119: 431-443.
131. Hromas R, Collins SJ, Hickstein D, Raskind W, Deaven LL, O'Hara P et al. A retinoic acid-responsive human zinc finger gene, MZF-1, preferentially expressed in myeloid cells. J Biol Chem 1991; 266: 14183-14187.
132. Perrotti D, Melotti P, Skorski T, Casella I, Peschle C, Calabretta B. Overexpression of the zinc finger protein MZF1 inhibits hematopoietic development from embryonic stem cells: Correlation with negative regulation of CD34 and c-myb promoter activity. Mol Cell Biol 1995; 15: 6075-6087.
133. Gaboli M, Kotsi PA, Gurrieri C, Cattoretti G, Ronchetti S, Cordon-Cardo C et al. Mzf1 controls cell proliferation and tumorigeneis. Genes Dev 2001; 15: 1625-1630.
134. Nelson WJ, Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science 2004; 303: 1483-1487.
135. Koptyra M, Falinski R, Nowicki MO, Stoklosa T, Majsterek I, Nielborowska-Skorska M et al. BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood 2006; 108: 319-327.
136. Calin GA, Croce CM. Chromosomal rearrangements and micro-RNAs: A new cancer link with clinical implications. J Clin Invest 2007; 117 2059-2066.
137. Eiring AM, Neviani P, Calin GA, Roy DC, Croce CM, Perrotti D. MicroRNAs act as decoy molecules to restore granulocytic maturation of differentiation-arrested BCR/ABL+ myeloid precursors. Blood 2007; 110: 17a (abstract #31).
138. Perrotti D, Cesi V, TRotta R, Guerzoni C, Santilli GG, Campbell K et al. BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2. Nat Genet 2002; 30: 48-58.
139. Perrotti D, Neviani P. From mRNA metabolism to cancer therapy: Chronic myelogenous leukemia shows the way. Clin Cancer Res 2007; 13 1638-1642.
140. Bueno MJ, de Castro IP, de Cedron MG, Santos J, Calin GA, Cigudosa JC et al. Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell 2008; 13: 496-506.
141. Brazma D, Grace C, Howard J, Melo JV, Holyoke T, Apperley JF et al Genomic profile of chronic myelogenous leukemia: Imbalances associated with disease progression. Genes Chromosomes Cancer 2007; 46: 1039-10501.
142. Mullighan CG, Miller CB, Radtke I, Phillips LA, Dalton J, Ma J et al BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 2008; 453: 110-114.
143. Fröhling S, Scholl C, Levine RL, Loriaux M, Boggon TJ, Bernard OA et al. Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell 2007; 12: 501-513.
144. Walters DK, Mercher T, Gu TL, O'Hare T, Tyner JW, Loriaux M et al. Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell 2006; 10: 65-75.
145. Tyner JW, Walters DK, Willis SG, Luttropp M, Oost J, Loriaux M et al RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia. Blood 2008; 111: 2238-2245.
146. Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant CML. Nat Rev Cancer 2007; 7: 345-356.
147. Giles FJ, Cortes J, Jones D, Bergstrom D, Kantarjian H, Freedman SJ. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T3151 BCR-ABL mutation. Blood 2007; 109: 500-502.
148. Paquette RL, Shah NP, Sawyers CL, Martinelli G, John N, Chalukya M et al. PHA-739358, an aurora kinase inhibitor, induces clinical responses in chronic myeloid leukemia harboring T3151 mutations of BCR-ABL. Blood 2007; 110: 312a (abstract 1030).
149. Shah NP, Kasap C, Paquette R, Cortes J, Pinilla J, Talpaz M et al. Targeting drug-resistant CML and Ph+-ALL with the spectrum selective protein kinase inhibitor XL228. Blood 2007; 110: 146a (abstract #474).
150. Cortes J, Roboz GJ, Kantarjian H, Feldman E, Karp J, Pollack A et al A Phase I dose escalation study of KW-2449, an oral multi-kinase inhibitor against FLT3, Abl, FGFR1 and aurora in patients with relapsed/ refractory AML, treatment resistant/intolerant CML, ALL and MDS. Blood 2007; 110: 277a (abstract #909).
151. Rivera VM, Xu Q, Wang F, Snodgrass J, O'Hare T, Corbin AS et al. Potent antitumor activity of AP24534, an orally active inhibitor of Bcr-Abl variants including T3151, in in vitro and in vivo models of chronic myeloid leukemia (CML). Blood 2007; 110: 312a-313a, (abstract #1032).
152. Lewis HA, Zhang F, Romero R, Bounaud PY, Wilson ME, Gosberg A. Co-crystal structures of 7-azaindole Inhibitors of wild-type and T3151 imatinib-resistant mutant forms of the BCR-ABL tyrosine kinase. Blood 2007; 110: 308a (abstract #1018).
153. T3151 and preempts in vitro resistance when combined with nilotinib or dasatinib. Proc Nat Acad Sci USA 2008; 105: 5507-5512.
154. Nagar B, Hantschel O, Young MA, Scheffzek K, Veach D, Bornmann W et al. Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell 2003; 112: 859-871.
155. Adrian FJ, Ding Q, Sim T, Valenta A, Sloan S, Liu Y et al. Allosteric inhibitors of Bcr-Abl dependent proliferation. Nat Chem Biol 2006; 2: 95-102.
156. van Etten RA, Chan WW, Zaleskas VM, Evangelista P, Lazarides K, Peng C et al. DCC-2036: A novel switch pocket inhibitor of ABL tyrosine kinase with therapeutic efficacy against BCR-ABL T3151 in vitro and in a CML mouse model. Blood 2007; 110: 142a-143a, (abstract # 463).
157. Hexner EO, Serdikoff C, Jan M, Swider CR, Robinson C, Yang S et al Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood 2007; 111: 5663-5671.
158. Li Z, Xu M, Xing S, Ho WT, Ishii T, L Qi et al. Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth. J Biol Chem 2007; 282: 3428-3432.
159. Pardanani A. JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. Leukemia 2008; 22: 23-30.
160. Wernig G, Kharas MG, Okabe R, Moore SA, Leeman DS, Cullen DE et al Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 2008; 13: 311-320.
161. Geron I, Abrahamsson AE, Barroga CF, Kavalerchik E, Gotlib J, Hood JD et al. Selective inhibition of a JAK2-driven erythroid differentiation of polycythemia vera progenitors. Cancer Cell 2008; 13: 321-330.
162. Lasho TL, Tefferi A, Hood JD, Verstovsek S, Gilliland DG, Pardanani A. TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients. Leukemia 2008; 22: 1790-1792.
163. Verstovsek S, Tefferi A, Kornblau S, Thomas D, Cortes J, Ravandi-Kashani F et al. Phase II study of CEP701, an orally available JAK2 inhibitor, in patients with primary myelofibrosis and post polycyhyenia vera/essential thrombocythemia myelofibrosis. Blood 2007; 110 1037A (abstract #3543).
164. Verstovsek S, Pardanani AD, Shah NP, Sokol L, Wadleigh M, Gilliland DG et al. A phase I study of XL019, a selective JAK2 inhibitor, in patients with primary myelofibrosis and post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood 2007; 110: 170a (abstract #553).
165. Verstovsek S, Kantarjian H, Pardanani AD, Thomas D, Cortes J, Mesa R et al. NCB018424, an oral selective JAK2 inhibitor, shows significant clinical acitivity in a phase I/II study in patients with primary myelofibrosis (PMF) and post polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF). Blood 2007; 110 171a (abstract #558).
166. Fridman J, Nussenzveig R, Liu P, Rodgers J, Burn T, Haley P et al. Discovery and preclinical characterization of INCB018414, a selective JAK2 inhibitor for the treatment of myeloproliferative disorders. Blood 2007; 110: 1035A (abstract #3538).
167. Zaleskas VM, Chan WW, Evangelista P, Lazarides K, Chopra R, Zinda M et al. A selective and potent oral inhibitor of the JAK2 tyrosine kinase reverses polycythemia and leukocytosis induced by JAK2 V617F in a mouse model. Blood 2007; 110: 171a (abstract #557).
168. Pardanani A, Hood J, Lasho Y, Levine RL, Martin MB, Noronha G et al TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia 2007; 21: 1658-1668.